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Abstract
Background: Some studies have suggested that transdermal administration of glyceryl trinitrate (GTN; nitroglycerin)
in the first few hours after symptom onset increases the chance of a favourable outcome after ischaemic stroke or
intracerebral haemorrhage, possibly through an increase in intracranial collateral blood flow and a reduction in
blood pressure. The Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin
Patch (MR ASAP) aims to assess the effect of transdermal GTN, started within 3 h after stroke onset in the prehospital
setting, on functional outcome at 90 days in patients with acute ischaemic stroke or intracerebral haemorrhage.
Methods: MR ASAP is a phase III, multicentre, randomised, open-label clinical trial with a blinded outcome assessment.
A total of 1400 adult patients with suspected stroke and a systolic blood pressure≥ 140mmHg will be randomised to
transdermal GTN (5mg/day), administered as a transdermal patch by paramedics in the prehospital setting within 3 h
of stroke onset and continued for 24 h or to standard care. The primary outcome is the score on the modified Rankin
Scale (mRS) at 90 days, analysed with ordinal logistic regression. Secondary outcomes include blood pressure and
collateral circulation at hospital admission, neurological deficit measured with the National Institutes of Health Stroke
Scale at 24 h, and mortality and poor outcome (mRS score 3 to 6) at 90 days. This trial will be conducted in
the Netherlands and will use a deferred consent procedure. The trial is part of the Collaboration for New
Treatments of Acute Stroke (CONTRAST) programme.
Discussion: MR ASAP will assess whether very early administration of GTN improves outcome after stroke in
a setting where rates of intravenous thrombolysis and endovascular treatment for acute ischaemic stroke are
high. The deferred consent procedure facilitates prompt GTN treatment and will prevent delay to revascularisation
therapies. If early transdermal GTN treatment proves to be effective, this low-cost treatment can be readily
implemented into daily clinical practice.
Trial registration: ISRCTN Registry, ISRCTN99503308. Registered on 2 January 2018.
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Prehospital, Randomised controlled trial
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Background
Despite recent advances in the treatment of patients with
acute ischaemic stroke or intracerebral haemorrhage,
about half of the patients still have a poor outcome [1].
Treatments with the largest benefit—intravenous thromb-
olysis and endovascular treatment—are indicated for a
relatively small proportion of patients. Hence, there is a
need for additional treatments applicable to a large range
of patients with acute stroke.
Potential therapeutic targets in patients with acute
stroke include improvement of collateral blood flow, in
case of cerebral ischaemia, and reduction of blood pres-
sure. High admission blood pressure in patients with is-
chaemic stroke or intracerebral haemorrhage has
consistently been associated with poor outcome and is
an easily modifiable factor [2].
In patients with acute intracerebral haemorrhage,
rapid blood pressure lowering may be effective and is
recommended in international guidelines [3, 4]. In pa-
tients with acute ischaemic stroke, the benefit of acute
blood pressure lowering is even less certain [5]. After oc-
clusion of an intracranial artery, blood supply to the po-
tentially salvageable penumbra is dependent on
collateral arteries, which can be defined as pre-existent
artery-to-artery anastomoses that can provide blood to
brain tissue when the primary supply pathways fail [6].
A systemic blood pressure reduction could lead to de-
creased blood supply to the ischaemic territory and in-
creased ischaemic damage because of impaired cerebral
autoregulation. By contrast, augmented collateral blood
flow to the penumbra before recanalisation could reduce
the extent of irreversible damage and might lead to a
better functional outcome [7]. In addition, the chance of
a favourable outcome after endovascular treatment is
greatest in patients with good collateral blood flow and
much smaller in patients with absent or poor collaterals
[6, 8]. Therefore, optimising collateral perfusion may im-
prove outcome after intravenous thrombolysis or endo-
vascular treatment. Nitric oxide donors are candidate
drugs for augmentation of collateral blood flow and
blood pressure reduction by their vasodilatory effects
[9]. In a meta-analysis of animal studies modelling acute
ischaemic stroke, nitric oxide donors increased cerebral
blood flow and reduced infarct size [10].
Glyceryl trinitrate (GTN), or nitroglycerin, is a nitric
oxide donor and a systemic and cerebral vasodilator.
The effects of transdermal administration of GTN have
been tested in six randomised clinical trials in patients
with acute ischaemic stroke or intracerebral haemor-
rhage [11–16]. Of these trials, the Efficacy of Nitric
Oxide in Stroke (ENOS) trial was the largest, with 4011
patients included within 48 h after stroke onset [12]. An
individual data meta-analysis (n = 4197) of the first five
trials did not show an effect on functional outcome in
the overall patient population. However, in a predefined
subgroup of 312 patients randomised within 6 h of
stroke onset, GTN reduced the risk of a poor functional
outcome and death in a time-dependent manner. Benefit
was observed both in patients with ischaemic stroke and
in those with intracerebral haemorrhage. Compared to
controls, GTN reduced systolic blood pressure at 1–2 h
by an average of 9.4 mmHg [11].
Of the abovementioned 312 patients, 41 were enrolled
in the ambulance-based phase II Rapid Intervention with
Glyceryl Trinitrate in Hypertensive Stroke (RIGHT) trial.
This trial assessed the feasibility and safety of prehospital
treatment with GTN, started within 4 h of stroke onset
[13]. Early administration of GTN lowered systolic blood
pressure by 21 mmHg at 15 min after randomisation and
by 18mmHg at 2 h compared with controls, but was
safe and associated with improved functional outcome.
The phase III RIGHT-2 trial assessed the safety and ef-
ficacy of transdermal GTN, started within 4 h of symp-
tom onset and before admission to the hospital, in 1149
patients with presumed stroke. The results of this trial
were published one year after the Multicentre Rando-
mised trial of Acute Stroke treatment in the Ambulance
with a nitroglycerin Patch (MR ASAP) had started. In
RIGHT-2, very early administration of transdermal GTN
did not improve functional outcome at 90 days [17].
MR ASAP aims to assess the effect of transdermal
GTN, started within 3 h of symptom onset in the prehos-
pital setting, on functional outcome at 90 days in patients
with acute ischaemic stroke or intracerebral haemorrhage.
Secondary objectives are to assess whether the effects of
transdermal GTN on functional outcome are consistent
across specific subgroups of patients, i.e. those with: (1) is-
chaemic stroke; (2) ischaemic stroke treated with endovas-
cular treatment; or (3) intracerebral haemorrhage; and to
assess the effects of GTN on collaterals, size of the ischae-
mic core and the amount of salvageable brain tissue on
admission to the hospital.
Methods/design
Study design
MR ASAP is a phase III multicentre clinical trial with
randomised treatment allocation, open-label treatment
and blinded endpoint assessment (PROBE) (Fig. 1). In
this trial, prehospital treatment with transdermal GTN
in a dose of 5 mg/day for one day will be compared with
standard care, in 1400 (2 × 700) patients with suspected
stroke.
Patient population
The study population will consist of patients aged ≥ 18
years in the prehospital setting, in whom the attending
paramedic diagnoses the patient with probable stroke
with a moderately severe to severe deficit. Inclusion
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criteria are listed in Table 1 and exclusion criteria in
Table 2. Several exclusion criteria are labelled as ‘known’,
indicating that the patient should be excluded from par-
ticipation in the trial only if the paramedic is aware of
the presence of an exclusion criterion.
Randomisation and treatment
Patients will be randomised 1:1 to open-label GTN (5
mg/day for one day) administered as a transdermal
patch by paramedics in the prehospital setting within 3 h
of stroke onset in addition to standard care, or to stand-
ard care alone (Fig. 2; Additional file 1: Figure S1).
Trained paramedics will randomise patients through a
secure web-based electronic application with real-time
data validation, using random block sizes without strata.
If patients are randomised to treatment with GTN but
prove not to have a transient ischaemic attack, ischaemic
stroke or intracerebral haemorrhage after examination in
the hospital, the patch will be removed but patients will
be followed-up as part of this study. If during the course
of the first 24 h it becomes apparent that the patient did
not fulfil the inclusion or exclusion criteria, the patch
will also be removed. In case of hospital discharge before
24 h, the patch will be removed upon discharge. Other-
wise, the nitroglycerin patch will be removed at 24 h.
The patch will be removed by trained study personnel
upon instruction of a local investigator.
Patients in each study group will be treated according
to national and international guidelines and local proto-
cols of ischaemic stroke, intracerebral haemorrhage or
any other condition that may be diagnosed. Participation
in this study does not preclude inclusion in a subsequent
intervention study, as long as this is not directed at
blood pressure modification.
Outcomes
The main study outcome is functional outcome, assessed
with the modified Rankin Scale (mRS) at 90 ± 14 days
[18]. Secondary outcomes include but are not limited to:
collateral circulation assessed with computed tomog-
raphy (CT) angiography and sizes of the infarct core and
perfusion deficit on CT perfusion on admission; neuro-
logical deficit measured with the National Institutes of
Health Stroke Scale at 24 h; mortality, poor functional
outcome (mRS 3 to 6), disability assessed with the
Barthel Index, [19] and quality of life assessed with the
EuroQol-5D-5L [20] at 90 days; and home time [21] and
patient location over the first 90 days.
Safety outcomes are serious adverse events; hypotension
or hypertension requiring clinical intervention; and symp-
tomatic intracerebral haemorrhage, scored according to
the Heidelberg Bleeding Classification, [22] all in the first
seven days or until discharge, if earlier.
Study procedures
Baseline characteristics assessed by the paramedic will
be included in the prehospital eCRF via a mobile device
that is connected to the Internet. The system randomises
the patient and also allocates a unique subject identifica-
tion number, with sequential numbering per ambulance
service. Blood pressure and pulse will be assessed at
baseline in the prehospital setting and at hospital
Fig. 1 Trial logo
Table 1 Inclusion criteria
Age≥ 18 years
Probable diagnosis of acute stroke, as assessed by the paramedic in the
prehospital setting
Score of 2 or 3 on the Face-Arm-Speech Test (FAST)
Systolic blood pressure≥ 140mmHg
Possibility to start the trial treatment within 3 h of symptom onset
Intention to transport the patient to one of the participating hospitals
Written informed consent (deferred)
Table 2 Exclusion criteria
Considerable pre-stroke dependency in activities of daily living, defined
as staying in a chronic nursing home or rehabilitation centre
Known pregnancy or lactation
Indication for acute treatment with nitroglycerin or known use of
nitroglycerin in the previous 12 h
Known hypersensitivity to GTN, nitrates in general or adhesives used in
the patch
Glasgow Coma Scale < 8
Known with any of the following heart disorders: myocardial
insufficiency due to obstruction; aortic or mitral valve stenosis;
constrictive pericarditis; hypertrophic obstructive cardiomyopathy;
cardiac tamponade
Known marked anaemia, defined as haemoglobin < 5mmol/L
Known closed angle glaucoma
Known use of phosphodiesterase type-5 inhibitors (e.g. sildenafil)
mRS modified Rankin scale, GTN glyceryl trinitrate
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admission. Where assessed as part of routine clinical
practice during hospital admission, blood pressure and
pulse will be collected at hourly intervals in the first 6 h,
at 2-h intervals between 6 h and 24 h, and at 24-h (± 4
h) intervals thereafter. Body temperature will be col-
lected at hospital admission and at 24 ± 4 h. The score
on the Face-Arm-Speech Test (FAST) will be assessed in
the prehospital setting by the paramedic and the score
on the NIHSS at hospital admission by the treating
physician. The NIHSS will also be assessed at 24 ± 4 h
after study inclusion. During hospital admission no ad-
ditional imaging or laboratory tests are required, but
Fig. 2 Flow of patients in the MR ASAP trial. Adapted from Appleton JP, Scutt P, Dixon M, Howard H, Haywood L, Havard D, et al. Ambulance-
delivered transdermal glyceryl trinitrate versus sham for ultra-acute stroke: Rationale, design and protocol for the Rapid Intervention with Glyceryl
trinitrate in Hypertensive stroke Trial-2 (RIGHT-2) trial (ISRCTN26986053). Int J Stroke. 2019;14:191–206. https://doi.org/10.1177/1747493017724627.
*Performed as part of routine care. **If eligible and as part of routine care or within subsequent CONTRAST trial. CONTRAST Collaboration for New
Treatments of Acute Stroke, CT computed tomography, CTA computed tomography angiography, EVT endovascular treatment, IVT intravenous
thrombolysis, NIHSS National Institutes of Health Stroke Scale
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routinely performed imaging will be collected. Serious
adverse events will be registered until seven days or until
discharge, if earlier.
At 90 ± 14 days the scores on the mRS, Barthel Index,
EQ-5D-5L, home time and patient location will be
assessed by trained research personnel who are not
aware of the treatment allocation. Standardised reports
of the telephone interview will be used for the assess-
ment of outcome on the mRS at 90 days by a central
outcome committee, blinded to the allocated treatment.
Informed consent
This study evaluates a treatment initiated by paramedics
as soon as possible after stroke onset. Since most pa-
tients with acute neurological deficits are not capable of
decision-making, and to reduce treatment delays, MR
ASAP uses a deferred informed consent procedure, in
line with Dutch law [23]. This implicates that patients
are included and may receive the GTN patch in the am-
bulance before consent is obtained. Written informed
consent should be obtained as soon as reasonably pos-
sible. In patients randomised to GTN who decline to
participate, study medication will be stopped immedi-
ately. Patients who do not provide consent or withdraw
during the study will be asked explicitly if their data can
be used in a coded, non-traceable manner, to be able to
describe baseline and treatment characteristics for the
great majority of patients. If the patient continues to lack
decision-making capacity, a legal representative will be
asked to provide consent.
Data and Safety Monitoring Board
An independent Data and Safety Monitoring Board
(DSMB) will oversee the safety of patients in the trial
and the efficacy of the intervention under study. They
will work in accordance with a dedicated charter and
will follow processes recommended by the DAMOCLES
statement. The DSMB is formed by a professor of vascu-
lar medicine, a vascular neurologist and a cardiovascular
epidemiologist. An independent trial statistician will
combine data on treatment allocation with the clinical
data in order to report to the DSMB. With respect to
safety, the DSMB will conduct unblinded interim ana-
lyses after every 100 patients have completed follow-up.
With respect to efficacy, the DSMB will conduct interim
analyses after 900 patients had their final follow-up. The
DSMB may recommend early termination of the study
because of safety if the rate of a poor functional outcome
at 90 days is lower in the control group, p < 0.01 (nom-
inal, two-sided); or if the death rate at 90 days is lower
in the control group, P < 0.01 (nominal, two-sided); and
because of efficacy if the 99.9% confidence interval for
the difference between the mean mRS scores at 90 days
excludes the null hypothesis, that is, the groups are
significantly different at p < 0.001; or because of any
other reason the DSMB will find relevant to the trial.
Sample size estimates
MR ASAP is powered to detect a statistically significant
shift in the distribution of the scores on the mRS at 90
days in the overall study population, assuming an effect
that leads to a 7% absolute risk reduction (ARR) in poor
functional outcome (mRS 3 to 6) in the GTN group
compared with controls (48% vs 41%). The sample size
calculations are based on a simulation study with a pro-
portional odds model. The risk of a poor functional out-
come of 48% in this domain of patients is based on
findings in the Field Administration of Stroke Therapy –
Magnesium (FAST-MAG) trial, a trial including 1700
patients with suspected stroke in the prehospital setting
[24]. We assume that the use of covariate adjustment
will increase statistical efficiency by 20%, which is based
on the R2 (coefficient of determination) in the Multicen-
ter Randomized Clinical Trial of Endovascular Treat-
ment for Acute Ischemic Stroke in the Netherlands (MR
CLEAN) data of an adjustment model containing age,
pre-stroke mRS and items 4, 5a, 5b, 9 and 10 of the
NIHSS that correspond to the FAST score [25, 26]. A
total study size of 1280 patients allows for a power of
80% to detect a difference at a 5% significance level in
the scores on the mRS in patients treated with GTN
compared to controls. As we expect to include around
10% stroke mimics, in whom no treatment benefit is ex-
pected, we increased this sample size with 10% and aim
for inclusion of 1400 patients.
Statistical analyses
The primary effect estimate, which is the shift in the
mRS score at 90 days, will be assessed by means of or-
dinal logistic regression and expressed as a common
odds ratio with a 95% confidence interval. The statistical
analyses will be performed according to the intention-
to-treat principle and will therefore include patients with
a stroke mimic. Analyses will be adjusted for relevant
baseline characteristics including age, sex, stroke type,
score on the FAST at study inclusion, time from symp-
tom onset to randomisation, pre-stroke score on the
mRS and ambulance region. Before follow-up is com-
pleted, a final statistical analysis plan will be developed
that specifies the hypotheses to be tested and a descrip-
tion of treatment effects, statistical methodology and
subgroup analyses in detail.
Study organisation
MR ASAP is conducted by members of the Collaboration
for New Treatments of Acute Stroke (CONTRAST) and
investigators in the participating ambulance services and
hospitals. The CONTRAST consortium performs five large
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randomised clinical trials in acute stroke patients in the
Netherlands to test novel treatment strategies (Table 3). Pa-
tients enrolled in the MR ASAP trial can also participate in
one of the subsequent trials within the CONTRAST con-
sortium (https://www.contrast-consortium.nl) [27].
The sponsor of the trial is University Medical Cen-
ter Utrecht. The trial is led by two co-chief investiga-
tors (stroke neurologists at the University Medical
Center Utrecht and Amsterdam University Medical
Center, respectively), a coordinating investigator and a
trial executive committee that consists of eight neu-
rologists and two ambulance service physicians. The
writing committee will also be based on the trial ex-
ecutive committee. Each participating centre, includ-
ing each participating ambulance service, has a local
principal investigator. Publications will be made on
behalf of all MR ASAP investigators (https://www.
mrasap.nl) [28]. We plan to publish the main results
in a peer-reviewed journal, with authorship contribu-
tions according to the International Committee of
Medical Journal Editors (ICMJE) criteria.
All data will be entered into a web-based trial manage-
ment system that allows for edit and audit trials and has
range and date checks, by trained local physicians or re-
search nurses. Incoming data will be reviewed by the
central trial office. Local data will be carefully monitored
by checking the first three and thereafter a sample of
10% patient case report forms against source data.
Within the CONTRAST consortium, subcommittees will
be composed for outcome assessment, adverse event ad-
judication and imaging assessment.
Discussion
MR ASAP assesses the effect of transdermal GTN,
started within 3 h after stroke onset in the prehospital
setting, on functional outcome at 90 days in patients
with acute ischaemic stroke or intracerebral haemor-
rhage. Previous trials of acute stroke treatment started
by paramedics, FAST-MAG (United States), RIGHT and
RIGHT-2 (United Kingdom), have shown that enrolment
and very early treatment of acute stroke patients in the
prehospital setting is feasible [13, 17, 24]. The median
time intervals from symptom onset to study drug ad-
ministration were 45, 55 and 70min, respectively.
For patients with ischaemic stroke, timely restoration
of blood flow is a first priority. In randomised trials,
intravenous thrombolysis with alteplase and endovascu-
lar treatment have shown to increase the chance of a
favourable outcome in selected patients, [1, 29] with
earlier treatment associated with greater benefit [30].
However, in meta-analyses of these trials, about half of
the patients were dead or dependent at three months [1,
29]. One explanation for the lack of benefit in a consid-
erable number of patients is that much of the ischaemic
brain tissue may have sustained irreversible damage at
the time that the occluded artery is recanalised. Im-
proved collateral blood flow to the penumbra before the
start of intravenous thrombolysis or endovascular treat-
ment could reduce the extent of irreversible damage and
might lead to a better functional outcome [7]. In animal
studies of focal cerebral ischaemia, NO donors increased
cerebral blood flow and reduced infarct size, [10] but the
effects of GTN on collateral flow in patients with ischae-
mic stroke are still uncertain. These effects will be
assessed in MR ASAP with CT angiography and CT per-
fusion on admission to the hospital.
MR ASAP will include patients within 3 h of the onset
of symptoms suggestive of acute stroke. This very short
time window was selected because we assumed a greater
beneficial effect of transdermal GTN the sooner treat-
ment is started, as suggested in a pooled analysis of pre-
vious trials of GTN in patients with acute stroke, [11,
31] but not in RIGHT-2 [17]. Such very early treatment
is considered feasible in the majority of stroke patients
in the Netherlands. A cohort study of patients treated
with intravenous thrombolysis in a comprehensive
stroke centre in the Dutch capital showed a median
onset-to-door time of 71 min [32]. With the exception of
a short physical examination, no diagnostic work-up
needs to be performed before inclusion in this study;
therefore, rapid inclusion is possible.
For safety reasons, only patients with a systolic blood
pressure of ≥ 140 mmHg are eligible for inclusion in this
study. In RIGHT, systolic blood pressure at 15 min after
randomisation was 21mmHg lower in patients treated
with GTN than in controls, without an increase in
Table 3 Randomised trials within the CONTRAST consortium
Multicentre Randomised trial of Acute Stroke treatment in the Ambulance
with a nitroglycerin Patch (MR ASAP): pre-hospital augmentation of
collateral blood flow and blood pressure reduction
(ISRCTN99503308)
Multicentre Randomised CLinical trial of Endovascular treatment for
Acute ischaemic stroke in the Netherlands. The effect of concomitant
MEDication: heparin, antiplatelet agents, both or neither (MR CLEAN-
MED): antithrombotics to prevent microvascular occlusion after EVT
(ISRCTN76741621)
Intravenous treatment followed by intra-arterial treatment versus direct
intra-arterial treatment for acute ischaemic stroke caused by a proximal
intracranial occlusion (MR CLEAN-NO IV): immediate EVT without preced-
ing thrombolysis (ISRCTN80619088)
Multicentre Randomised Clinical Trial of Endovascular Stroke treatment
in The Netherlands for Late arrivals: (MR CLEAN-LATE): EVT in the 6 to
24 h time window (ISRCTN19922220)
The Dutch ICH Surgery Trial pilot study (DIST pilot study): minimally invasive
endoscopy-guided surgery for spontaneous intracerebral haemorrhage
(NCT03608423)
CONTRAST Collaboration for New Treatments of Acute Stroke, EVT
endovascular treatment, ICH intracerebral haemorrhage
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serious adverse events [13]. In the subgroup of patients
treated within 6 h of stroke onset in the above-
mentioned pooled analysis, GTN resulted in a 10 mmHg
lower systolic blood pressure at 1–2 h than standard
treatment. In the complete study population, 2.7% of the
patients treated with GTN required treatment for clin-
ical hypotension compared to 0.7% of controls, but no
increase in the rates of serious adverse events or death
was observed [11]. In RIGHT-2, GTN reduced systolic
blood pressure by 5.8 mmHg at hospital admission com-
pared with the control group. The complication rate was
similar for both groups [17]. GTN has also been shown
safe in patients with ipsilateral carotid stenosis [12].
The informed consent procedure in acute stroke re-
search is challenging. Besides fast diagnostic work-up
and initiation of time-dependent treatments in a person
with neurological deficits, informed consent must be ob-
tained from a vulnerable group of patients who often
lack decision-making capacity. In the Netherlands, de-
ferred informed consent is possible in emergency situa-
tions as long as circumstances prevent the provision of
informed consent and if inclusion in the trial may bene-
fit the person in urgent need of medical treatment [23].
For MR ASAP, we considered deferred consent justifi-
able and this has been approved by the Research Ethics
Committee. First, inclusion in this prehospital study
should not delay transportation to the hospital and re-
duce the possibility to receive effective treatments such
as intravenous thrombolysis or endovascular treatment.
Second, participation in the trial may be of direct benefit
to the patient in a time-dependent manner [11]. Third,
not only the very large majority of patients will lack
decision-making capacity due to their neurological
symptoms, but also most relatives can be considered not
capable of providing consent due to stress and the ne-
cessity of urgent treatment. Also, relatives are often not
available in the very acute setting. In addition, GTN was
safe in previous trials of acute stroke, with no difference
in total SAEs and death rates in patients treated with
GTN as compared with controls [11].
Since patients are enrolled before examination by a
stroke specialist and imaging, we have selected a score
of 2 or 3 on the FAST in addition to the clinical assess-
ment of a trained paramedic in order to keep the pro-
portion of patients with stroke-mimicking conditions as
small as possible. The FAST test is widely used by para-
medics in The Netherlands and yields a positive pre-
dictive value for true strokes up to 89% [33]. The
FAST-MAG trial and RIGHT trial have shown that the
proportion of enrolled patients with stroke-mimicking
conditions can be as small as 4–12%. We have
accounted for 10% stroke mimics in the sample size
calculation of MR ASAP for whom no harm of GTN
treatment is expected.
The RIGHT-2 trial has recently investigated the effects
of prehospital stroke treatment with a GTN patch in the
United Kingdom [34]. Similar to MR ASAP, in RIGHT-2
the paramedic assessed the eligibility criteria for enrol-
ment in the trial and starts study treatment. Likewise,
RIGHT-2 used a FAST score of 2 or 3 as an inclusion
criterion. In contrast to MR ASAP, patients were en-
rolled with a systolic blood pressure ≥ 120 mmHg. MR
ASAP will be performed in a setting where approxi-
mately 20% of patients with acute ischaemic stroke re-
ceive intravenous thrombolysis and 5% endovascular
treatment [35]. While informed consent is deferred in
MR ASAP, in RIGHT-2 paramedics had to assess
decision-making capacity (Additional file 2: Table S1).
After completion of the trials, data of RIGHT-2 and MR
ASAP will be pooled to improve the accuracy of esti-
mates of the effect size.
In summary, improvement of intracranial collateral
circulation and blood pressure reduction are potential
targets for acute stroke treatment. MR ASAP assesses
the effects of prehospital treatment with a GTN patch in
suspected stroke. A deferred consent procedure is used
to reduce delays in transport and treatment in the hos-
pital. In case of effectiveness of GTN, the pragmatic de-
sign of the trial will simplify the implementation of GTN
treatment in clinical practice Additional file 4.
Trial status
Currently four ambulance services are enrolling patients
in MR ASAP with possible referral to 14 participating
hospitals. The first patient was included on 4 April 2018.
By February 2019, 180 patients had been included. Re-
cruitment by at least four other ambulance services will
commence in 2019. Final follow-up is expected in 2021.
The current article is based on protocol version 1.5 (De-
cember 2018).
After the presentation and publication of the results
of RIGHT-2, inclusion in the trial was interrupted
temporarily to allow DSMB review of all data from
previous trials and safety and outcome date of the
first 100 patients included in MR ASAP. This interim
analysis was performed on 30 April 2019 and based
on the advice of the DSMB, the trial will be restarted
in July 2019.
Additional files
Additional file 1: Figure S1. Schedule of enrolment, interventions and
assessments. (PDF 128 kb)
Additional file 2: Table S1. Comparison of MR ASAP trial with RIGHT-2
trial. (PDF 29 kb)
Additional file 3: List of CONTRAST work package leaders. (PDF 31 kb)
Additional file 4: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (PDF 58 kb)
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